Why does Hemoglobin A1c (HbA1c) remain unchanged despite maximal dosing of Jardiance (Empagliflozin), Metformin, and low-dose Rybelsus (Semaglutide)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 17, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the Guidelines

A patient's HbA1c level may not decrease in response to maximum dosing of Jardiance (empagliflozin 25mg daily), metformin (2000mg daily), and low-dose Rybelsus (semaglutide 3mg daily) due to several factors, including inadequate insulin secretion, insulin resistance, or glucagon excess 1.

Possible Causes

  • Underlying conditions: The presence of underlying conditions such as pancreatic beta-cell dysfunction, kidney disease, or cortisol excess may also contribute to the lack of response 2.
  • Duration of therapy: The duration of therapy, which may be less than 6 months, may not be sufficient to achieve optimal glycemic control, as the full effects of these medications may take longer to manifest 3.
  • Medication limitations: Certain medications, such as sulfonylureas, can cause hypoglycemia if clinicians are overzealous to achieve a tight target in some patients, while others like GLP1-agonists and SGLT2-inhibitors can achieve reductions in HbA1c without hypoglycemia and favorable CVD outcomes 1.

Treatment Considerations

  • Individualized approach: Each patient requires an individualized approach to achieve the lowest possible HbA1c with the least amount of hypoglycemia and medication burden 1.
  • Combination therapy: Combination therapy with metformin and other agents, such as SGLT2 inhibitors or GLP-1 receptor agonists, may be effective in achieving HbA1c targets without meaningful hypoglycemia 1.
  • Patient-centered care: Patient-centered care and personalized treatments are essential to balance the scientific evidence with the unique needs of each patient 1.

From the FDA Drug Label

The provided drug labels do not directly address the question of why Hemoglobin A1c (HbA1c) remains unchanged despite maximal dosing of Jardiance (Empagliflozin), Metformin, and low-dose Rybelsus (Semaglutide).

The FDA drug label does not answer the question.

From the Research

Factors Affecting Hemoglobin A1c (HbA1c) Levels

  • The provided studies do not directly address why HbA1c remains unchanged despite maximal dosing of Jardiance (Empagliflozin), Metformin, and low-dose Rybelsus (Semaglutide) 4, 5, 6, 7, 8.
  • However, several factors can influence HbA1c levels, including the effectiveness of the treatment regimen, patient adherence, and individual characteristics such as age, duration of diabetes, and presence of comorbidities 5, 6.
  • The American Diabetes Association recommends maintaining HbA1c levels below 7% for most adults, but this target may need to be adjusted based on individual patient factors 5, 8.

Treatment Regimens and HbA1c Control

  • The use of metformin in combination with other antidiabetic medications, such as insulin or GLP-1 receptor agonists, can improve HbA1c control 4, 5.
  • However, the effectiveness of these regimens can vary depending on individual patient factors, such as age, duration of diabetes, and presence of comorbidities 5, 6.
  • Early attainment of HbA1c targets is important for long-term glycemic control, and timely modification of treatment strategies may be necessary to minimize therapeutic inertia 6.

Indicators of Glycemic Control

  • HbA1c is a widely used indicator of long-term glycemic control, but it may not reflect short-term changes in blood glucose levels 7.
  • Other indicators, such as glycated albumin and 1,5-anhydroglucitol, may be useful for assessing glycemic control and identifying rapid changes in hyperglycemia 7.
  • The choice of indicator may depend on individual patient factors and the specific goals of treatment 7, 8.

Related Questions

When should premixed insulin 70/30 (70% intermediate‑acting insulin, 30% rapid‑acting insulin) be initiated according to the ADA 2025 guidelines in an 80‑kg adult patient on metformin and a sulfonylurea who has not achieved glycemic targets?
What does a basal insulin level of 2.3 (microunits per milliliter) indicate in a 48-year-old man with no known diabetes?
In a 27‑year‑old woman with type 2 diabetes, weight 86.6 kg, creatinine 0.40 mg/dL, GFR > 90 mL/min, currently taking neutral protamine Hagedorn (NPH) insulin 32 U at 8 am, dexamethasone 20 mg daily, with an insulin‑to‑carbohydrate ratio (ICR) of 1 U per 3 g carbohydrate and an insulin sensitivity factor (ISF) of 25 mg/dL per U, and blood glucose values of 207 mg/dL at 9 am, 229 mg/dL after a 90‑g carbohydrate meal, 373 mg/dL at 5 pm, 340 mg/dL at 9 pm, and 286 mg/dL at 2 am, what should the NPH basal insulin dose, ISF, and ICR be adjusted to?
A 28‑week‑gestation pregnant woman weighing 114 kg has a fasting blood glucose of 157 mg/dL while on insulin glargine (Lantus) 40 units daily; how much should the insulin glargine dose be increased?
For a 19‑year‑old with type 1 diabetes, weight 86 kg, creatinine 0.74 mg/dL, GFR > 90 mL/min, bicarbonate 17 mmol/L, anion gap 13, currently on metformin 750 mg daily and insulin glargine (Lantus) 15 U at 8 am and 35 U at 8 pm with carbohydrate‑to‑insulin ratios of 1 U per 6 g carbs at breakfast and 1 U per 7 g carbs at lunch/dinner and an insulin‑sensitivity factor of 25 mg/dL per U, and blood glucose values of 184 mg/dL (8 am), 220 mg/dL (noon), 262 mg/dL (5 pm), 237 mg/dL (10 pm), and 97 mg/dL (4 am), what should the morning and evening Lantus doses be and what should the insulin‑sensitivity factor and insulin‑to‑carbohydrate ratios be adjusted to?
Can increased bone marrow activity on a Positron Emission Tomography (PET) scan indicate relapsed Hodgkin lymphoma without other detectable disease activity?
Are dental blocks with bupivacaine (Marcaine) safe during pregnancy?
What is the dosage and frequency of Bactrim (Trimethoprim/Sulfamethoxazole) for cellulitis?
When to use antibiotics in mastitis (inflammation of the breast tissue)?
What part of the mouth does the eustachian tube drain to?
What are the medical uses of boric acid?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.